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Summary
 
Cysteine proteases of the CED-3 and ICE family have been recently proposed as the ultimate
executioners in several mammalian cell death pathways. Among them, the cysteine protease
CPP32 has been shown to participate in programmed cell death (PCD), or apoptosis, affecting
lymphoid cells in vitro. In the thymus, negative selection is a mechanism through which devel-
oping thymocytes expressing a TcR with high affinity for self peptide–MHC complexes are
eliminated by PCD. In order to investigate the role of CPP32 in thymic apoptosis, isolated
thymocytes were submitted to cell surface CD3 crosslinking by immobilized anti-CD3 mAb or
to dexamethasone treatment. Although apoptosis occurred in the absence or after crosslinking
with anti-CD3 mAb, specific activation of CPP32, as assessed by the extent of proteolytic
cleavage of the p32 zymogen, was only detected in thymocytes cultured in the presence of the
immobilized antibody or dexamethasone. This activation was a very early event during apopto-
sis as it occurred before the exposure of phosphatidyl serine to the upper side of the cell mem-
brane. This was observed both in anti–CD3- and dexamethasone-induced apoptosis. More-
over, using mice transgenic for pigeon cytochrome C (PCC)-specific TcR, we were able to
show that, after injection of PCC, the activation of CPP32 and cleavage of its substrate oc-
curred in thymocytes obtained from mice expressing a permissive MHC haplotype for PCC
presentation (H-2k). Moreover, PCC induced apoptosis was blocked by the caspase inhibitor
zVAD. While spontaneous apoptosis was not accompanied by detectable levels of CPP32 pro-
cessing, it was characterized by the proteolysis of poly(ADP-ribose) polymerase (PARP) and
was blocked by the cysteine protease inhibitor, zVAD-CH2F. Taken together, these results
support the concept that CPP32 is among the earliest effectors of the pathway leading to nega-
tive selection of autoreactive thymocytes. Our results also suggest the involvement of a distinct
CPP32-like cysteine protease in spontaneous apoptosis of thymocytes.
 
T
 
he basic cellular machinery carrying out programmed
cell death (PCD),
 
1
 
 or apoptosis, is thought to involve
the active participation of endogenous cellular proteases that
act as direct effectors as well as regulatory factors of apopto-
sis (1–3). Among these proteases, the cysteine protease
CPP32 (YAMA, apopain or caspase 3) has recently been
shown to be a key player in PCD of mammalian cells (4–6).
CPP32 is a 32-kD protein that, like other cysteine pro-
teases, is synthesized as an inactive precursor that undergoes
proteolytic conversion to eliminate a 3-kD NH
 
2
 
-terminal
propeptide and to generate the active heterodimer enzyme
composed of 12-kD (p12) and 17-kD (p17) subunits (5).
Among its known substrates are key enzymes involved in
cellular repair and maintenance. They include poly(ADP-
ribose) polymerase (PARP) (5, 6), the 70-kD unit of the
U1-ribonucleoprotein (U1-70kD) (7), the catalytic subunit
of DNA-dependent protein kinase (DNA-PK) (7) as well
as sterol-regulatory element binding proteins (SREBP) (8),
the GDP dissociation inhibitor (D4-GDI) for the Ras-related
Rho family GTPases (9), and huntingtin, a cystoplasmic
protein involved in the neurodegenerative Huntington’s
disease (10). CPP32 proteolytic activity occurs at specific
 
1. 
 
Abbreviations used in this paper:
 
 PARP, proteolysis of poly(ADP-ribose)
polymerase; PCC, pigeon cytochrome C; PCD, programmed cell death;
PI, propidium iodide; SREBP, sterol-regulatory element binding pro-
teins.
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(P4)Asp-X-X-Asp(P1) motives and cleaves the substrates
between their functional domains (5–9).
PCD takes an integral part in the development and ho-
meostasis of the immune system. The involvement of CPP32
in PCD of lymphoid cells has been documented. For ex-
ample, Fas-mediated apoptosis, which is thought to be es-
sential for silencing immune responses as well as for the
elimination of autoreactive cells in periphery, involves the
activation of CPP32 (11–14). Moreover, cell-mediated death
delivered by antigen-specific CTL involves the proteolytic
activation of CPP32 by granzyme B (15). All these studies,
however, have been performed on transformed cell lines,
hybridomas and in cell free systems. Evidence for the pro-
teolytic activation of CPP32 in in vivo models of apoptosis
is still lacking. In the thymus, apoptosis is known to be a
crucial step of thymic differentiation. It affects immature
CD4
 
1
 
CD8
 
1
 
 thymocytes expressing antigen receptors with
potentially harmful reactivity for self (negative selection)
(16–19) as well as cells lacking receptors capable of binding
peptide–MHC complexes (death by neglect) (20). Whether
the cysteine protease CPP32 participates in negative selec-
tion in the thymus is not known. In this report, we de-
scribe the specific involvement of CPP32 in this critical
step of T cell development.
 
Materials and Methods
 
Mice.
 
4–6-wk-old inbred C57Bl/6 and B10.D2 female mice
were obtained from Charles River (Saint Constant, Canada) and
Jackson Laboratories (Bar Harbor, Maine), respectively. AD10
H-2k mice transgenic for pigeon cytochrome C–specific TcR have
been described previously (21). AD10 H-2b congenics were gen-
erated by successive back-crosses with C57BL/6 mice.
 
Assay for Apoptosis.
 
Thymocytes (2 
 
3 
 
10
 
6
 
 cells per well) were
cultured in 24-well culture plates in complete RPMI-1640 me-
dium (GIBCO BRL, Burlington, Canada) (0.5 ml per well) sup-
plemented with 10 mM Hepes, 5 mM 
 
l
 
-glutamine and 10% FCS.
Cells were incubated alone, or in the presence of immobilized af-
finity-purified 145-2C11 mAb (hamster anti–mouse CD3
 
e
 
; 10 
 
m
 
g
per ml per well), or with dexamethasone (10
 
-6
 
 M from a 35-mM
stock solution prepared in ethanol). After incubation at 37
 
8
 
C,
cells (5 
 
3 
 
10
 
5
 
) were harvested and the presence of apoptotic cells
was detected by multiparameter flow cytometry with propidium
iodide (PI) and FITC-conjugated annexin V (Nexins Research
B.V., Hoeven, Netherlands) (22). Cells were labeled with an-
nexin V-FITC according to manufacturer’s instructions. Immedi-
ately before analysis, PI was added to single-cell suspensions (2 
 
m
 
g
per ml final dilution). Cell fluorescence was analyzed on a FAC-
SCAN
 
Ò
 
 (Becton Dickinson, Mississauga, Canada). Acquisition of
data was performed without gating on forward light scatter. A
minimum of 10
 
4
 
 events were acquired for each sample.
For protease inhibitor experiments, thymocytes (4 
 
3 
 
10
 
6
 
 cells
per ml) were cultured with or without immobilized anti-CD3 mAb
or dexamethasone in the presence of the ICE-family tripeptide
inhibitor benzyloxycarbonyl-valinyl-alaninyl-aspartyl(
 
o
 
-methyl)-
fluoromethylketone (zVAD-CH2F) (100 
 
m
 
M; Enzyme Systems
Products, Dublin, CA). Levels of apoptosis were measured as de-
scribed above.
In experiments where apoptosis was triggered in vivo, AD10.H-2k
and AD10.H-2b mice were challenged by a single intraperitoneal
injection of pigeon cytochrome C (1 mg per mouse) (Sigma
Chemicals, Mississauga, Canada) in HBSS. Mice were killed 16
or 24 h after injection and thymocytes were isolated and cultured
as described above with or without zVAD-CH2F as described
above.
 
Cell Sorting.
 
After incubation for 24 h in the presence of im-
mobilized anti-CD3, thymocytes were labeled with annexin V-FITC
as described above. Annexin V
 
1
 
 and annexin V
 
2
 
 cells were sorted
on a FACStar Plus
 
Ò
 
 (Becton Dickinson). Purity of each sorted
population was verified and was always 
 
.
 
99.5%.
 
Immunolabeling.
 
Specific staining was performed with PE-
conjugated rat anti–mouse CD4 mAb (GIBCO BRL) and with
biotin-conjugated rat anti–mouse CD8 mAb (GIBCO BRL) re-
vealed by streptavidin-TRIColor
 
Ò
 
 (Caltag, San Francisco, CA).
Optimal antibody dilutions were determined before use.
 
Production of Antiserum Specific for CPP32.
 
CPP32 cDNA, re-
verse-transcribed from whole RNA isolated from Jurkat cells, was
amplified by polymerase chain reaction using sense and anti-sense
oligonucleotides located on the coding sequence of CPP32 p20.
The oligonucleotides were: GGGATCCATGGAGAACACTGA-
AAACTC (sense) and ATGAATTCCCTAGTCTGTCTCAA-
TGCCACA (antisense). Amplified products were cloned in Blue
Script PBS KS
 
1
 
 (Stratagene, La Jolla, CA) and sequenced. Solu-
ble GST fusion protein was made using the pGEX 2Tk (Pharma-
cia, Baie d’Urfé, Canada). The protein was purified on Glu-
tathione Sepharose 4B columns (Pharmacia) and cleaved with
thrumbin. Rabbits were immunized intramuscularly and subcuta-
neously by five injections of purified protein (250 
 
m
 
g per injec-
tion at 4-wk intervals). First and second injections were made in
CFA and IFA, respectively. Specificity of the antiserum was
tested by Western blotting on Jurkat cells and mouse T cell hybri-
domas and compared with that of an anti-CPP32 mAb supplied
by Transduction Laboratories (Mississauga, Canada). The anti-serum
failed to show any signal when tested on ES cells homozygous for
CPP32 null mutation (Hakem, R., personal communication).
This confirmed that our anti-serum was specific to CPP32 and
did not cross react with other murine caspases.
 
Western Blotting.
 
Cells were washed with PBS, sonicated for
20 s in sample buffer (62.5 mM Tris-HCl pH 6.8; 6 M urea; 10%
glycerol; 2% SDS; 0.00125% bromophenol; 5% 
 
b
 
-mercaptoetha-
nol), and boiled for 3 min. Samples were resolved on SDS-PAGE
(10% acrylamide for anti-PARP, 15% acrylamide for anti-CPP32)
and transferred to nitrocellulose membrane (Hybond C Super;
Amersham, Oakville, Canada). Blots were blocked for 1 h at room
temperature in PBS containing 5% of nonfat dried milk. Mem-
branes were then incubated overnight with rabbit anti-sera to hu-
man CPP32 (see above) or to mouse PARP (a generous gift from
Dr. G. Poirier, Centre Hospitalier de l’Université Laval, Québec,
Canada) in PBS with 5% of nonfat dried milk under gentle shak-
ing. Membranes were washed three times in PBS containing urea
(2 M) and 0.05% Tween and twice in PBS containing 0.05%
Tween. For PARP antiserum, detection was achieved by incubat-
ing with goat anti–rabbit Ig antibodies conjugated to HRP (Jack-
son Laboratories) (1/2,500 in PBS with 0.05% Tween and 5% dried
milk). Detection for CPP32 antiserum was done with HRP-con-
jugated protein A (Amersham) (1/1,000 in PBS containing 5% dried
milk). After three washes in PBS containing 0.05% Tween, signals
were revealed with the enhanced chemiluminescence ECL West-
ern blotting kit (Amersham) and visualized by autoradiography.
 
Results
 
CPP32 Is Activated during Apoptosis Induced In Vitro by
Anti-CD3 Crosslinking and by Dexamethasone.
 
In four in- 
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dependent experiments, freshly isolated thymocytes were cul-
tured in medium alone at 4 or 37
 
8
 
C in the presence of im-
mobilized anti-CD3 mAb or dexamethasone. Cell viability
was assessed by flow cytometry using PI and FITC-conju-
gated annexin V staining. Early apoptosis has been charac-
terized by the loss of plasma membrane asymmetry and the
subsequent exposure of phosphatidylserine at the cell sur-
face (annexin V
 
1
 
) while cellular integrity is maintained as
evidenced by exclusion of PI (22). The combined use of PI
and FITC-annexin V therefore allows the simultaneous anal-
ysis of viable cells (PI
 
2
 
 annexin V
 
2
 
), cells in early apopto-
sis (PI
 
2
 
 annexin V
 
1
 
), and dead cells (PI
 
1
 
 annexin V
 
1
 
)
(Fig. 1, 
 
top
 
).
Cells kept at 4
 
8
 
C showed little signs of apoptotic cell death
even after 24 h of culture (Fig. 1, 
 
A–C
 
). Crosslinking cell
surface CD3 complexes decreased cell viability to 
 
z
 
45% of
viable cells after 24 h of culture (Fig. 1 
 
A
 
), while the rate of
apoptosis, as determined by the percentage of cells in early
apoptosis, increased progressively to reach 
 
z
 
15% after 24 h
(Fig. 1 
 
B
 
). As expected the number of dead cells increased
proportionally after anti-CD3 treatment (Fig. 1 
 
C
 
). Differ-
ences in both magnitude and kinetics of apoptosis were ob-
served between anti-CD3–mediated and spontaneous apop-
tosis. Indeed, and contrarily to what was observed with
anti-CD3 treatment, the level of early apoptosis at 37
 
8
 
C in-
creased during the first 6 h of culture to stabilize at 7–9%
for the next 18 h (about twofold lower than with anti-
CD3) (Fig. 1 
 
B
 
). Moreover in all our experiments the
number of viable cells after 24 h was always significantly
higher (
 
.
 
10–15%) in thymocyte cultures which had not
been submitted to anti-CD3 treatment (Fig. 1 
 
A
 
). Conversely,
the number of dead cells was reproducibly and significantly
lower in the latter cultures than in anti-CD3–treated ones
(Fig. 1 
 
C
 
). Taken together these results indicate that anti-
CD3 crosslinking was more efficient than culturing at 37
 
8
 
C
in inducing PCD and that this was due to a faster rate of
apoptosis. Finally, dexamethasone induced massive cell
death with a relative number of cells in early apoptosis
peaking at 58% after 6 h (Fig. 1 
 
B
 
). This was accompanied
by a quick drop in cell viability with a relative number of
viable cells reaching 
 
,
 
5% after 12 h of culture (Fig. 1 
 
C
 
).
To determine whether the activation of CPP32 is a com-
mon feature of different apoptotic pathways in thymocytes,
Western blots with anti-CPP32 rabbit serum were per-
formed in two independent experiments on total cell ly-
sates obtained from thymocyte cultures subjected to differ-
ent apoptotic stimuli. As mentioned earlier, activation of
CPP32 results from the proteolytic cleavage of the proen-
zyme form p32 into two subunits p17 and p12 (5). Results
illustrated in Fig. 2 
 
A
 
 show that anti-CD3 or dexametha-
sone treatments were able to activate CPP32. Indeed, the
presence of the p17 subunit was noticed as early as after 12 h
of culture with immobilized anti-CD3 and its abundance
increased progressively thereafter. Dexamethasone induced
a rapid and massive emergence of the p17 band as early as 6 h
after the initiation of culture. A direct correlation between
the appearance of the active form of CPP32 and the onset
of apoptosis was observed for both anti-CD3 and dexa-
methasone treatments. In addition, the levels of activated
CPP32 were directly proportional to the number of cells
undergoing apoptosis (Fig. 1 and 2 
 
A
 
). Altogether these re-
sults show the activation of CPP32 as an integral compo-
nent of these apoptotic pathways. In contrast, spontaneous
cell death that occurred at 37
 
8
 
C did not induce detectable
levels of CPP32 processing as assessed by the complete ab-
sence of the p17 subunit even upon 24 h of culture and
Figure 1. Time course of apo-
ptosis in isolated thymocytes cul-
tured alone or in the presence of
immobilized anti-CD3 mAbs or
dexamethasone. The upper panel
shows the flow cytometry mea-
surement of annexin V binding
(x axis) vs. propidium iodide up-
take (y axis) on thymocytes cul-
tured for 12 h in the presence of
immobilized anti-CD3. Viable
cells and cells in early apoptosis
are annexin V2 PI2 (A) and an-
nexin V1 PI2 (B), respectively.
Dead cells are annexin V1 PI1
(C). The lower panels display the
evolution of cell viability (A),
the percentage of cells in early
apoptosis (B) and the mortality
(C) in thymocyte populations in-
cubated at 48C (open square) or
cultured at 378C alone (closed
squares), in the presence of immo-
bilized anti-CD3 mAb (open circles)
or with dexamethasone (closed cir-
cles). This experiment produced
identical results in a total of four
independent occasions. 
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overexposure of the autoradiogram (Fig. 2 
 
A
 
 and data not
shown). The lack of CPP32 processing during spontaneous
apoptosis was not due to lower cell death than in cultures
with anti-CD3. Indeed, even at equal levels of cell death
for spontaneous apoptosis and for anti-CD3 treatment (af-
ter 24 and 18 h, respectively) (Fig. 1 
 
C
 
), CPP32 activation
still distinguished anti-CD3–mediated apoptosis (Fig. 2 
 
A
 
).
 
Spontaneous Apoptosis Is Characterized by PARP Cleavage
and Is Inhibited by zVAD-CH
 
2
 
F.
 
To determine whether
CPP32-like activity could be detected in apoptosis stimu-
lated by cell-surface crosslinking of CD3, by treatment with
dexamethasone or during spontaneous apoptosis, cell lysates
were blotted with rabbit antisera to mouse PARP. Cleav-
age of PARP by CPP32 and CPP32-like enzymes is known
to yield products of 
 
z
 
85 and 31 kD (5, 6). As shown in
Fig. 2 
 
B
 
, both anti-CD3 and dexamethasone treatments in-
duced the appearance of a specific 85-kD protein. This co-
incided with the activation of CPP32 (Fig. 2 
 
B
 
) and was
observed as early as after 12 h of culture with anti-CD3 mAb
and after 6 h with dexamethasone. Complete proteolysis of
PARP could be seen after 12 h of treatment with dexa-
methasone. Surprisingly, although the activation of CPP32
was not detected in thymocytes cultured alone at 37
 
8C (see
above), the cleavage of PARP was observed after 12 h of
culture under the same conditions (Fig. 2 B). Altogether,
these observations imply that induction of cell death in thy-
mocytes by anti-CD3 crosslinking or exposure to dexa-
methasone or during spontaneous apoptosis involves CPP32-
like activity. They also suggest that spontaneous apoptosis
of thymocytes activates (a) CPP32-like cysteine protease(s)
that is (are) able to cleave PARP.
The tripeptide zVAD-CH2F is a well known inhibitor
of cysteine proteases of ICE/CED-3 family, including
CPP32 (reference 23 and Fig. 3). To confirm the involve-
ment of CPP32-like activity in spontaneous apoptosis, the
inhibition profile of the tripeptide on thymocyte cultures
was determined. The results presented in Fig. 4 are repre-
sentative of two independent experiments. Interestingly,
zVAD-CH2F was a potent inhibitor of spontaneous apop-
tosis of thymocytes as well as apoptosis mediated either by
anti-CD3 mAbs or dexamethasone. Altogether, these re-
sults confirm the direct involvement of CPP32 and CPP32-
like proteases in thymocyte apoptosis.
Activation of CPP32 Is a Very Early Event in Thymocyte
Apoptosis. As mentioned above, after 6 h of treatment
with dexamethasone, usually 50–60% of thymocytes are in
early apoptosis whereas 5–20% of cells are in late apoptosis.
The massive activation of CPP32 at this time point (espe-
cially in the experiment presented in Fig. 1 C where only
6% of thymocytes are in late apoptosis), suggests that CPP32
activation occurs as soon as or before the exposure of the
phosphatidylserine at the upper side of the cell membrane.
The ability of zVAD-CH2F to inhibit annexin V staining
and CPP32 activation in thymocytes (Fig. 4) further suggests
that activation of cysteine proteases occurs before the loss
of membrane asymmetry. To determine whether CPP32
Figure 2. In isolated thy-
mocytes, CPP32 is activated
during apoptosis induced by
crosslinking of CD3 or exposure
to dexamethasone. Time course
of CPP32 activation (A) and
cleavage of PARP (B) in thy-
mocytes cultured at 48C, or at
378C alone, with immobilized
anti-CD3 mAb or with dexa-
methasone for the indicated time.
Cell lysates were electrophoresed,
and substrate cleavage was visual-
ized by immunoblotting as de-
scribed in Materials and Meth-
ods. The results presented in this
figure are representative of two
independent experiments.
Figure 3. zVAD-CH2F inhibits the processing of CPP32 and the
cleavage of PARP. CPP32 activation and cleavage of PARP in thymo-
cytes cultured with dexamethasone for 6 h in the presence or absence of
100 mM zVAD-CH2F. Cell lysates were electrophoresed, and substrate
cleavage was visualized by immunoblotting as described in Materials and
Methods.1507 Alam et al.
activation is a very early event of thymocyte apoptosis, a time
course of CPP32 activation was carried out on thymocytes
stimulated with dexamethasone. As illustrated in Fig. 5 a,
treatment with dexamethasone did not induce significant
apoptosis, as evidenced by the absence of annexin V1 PI2,
during the first 150 min. After this initial lag an abrupt in-
crease in the relative number of cells in early apoptosis was
noted. A plateau in percentage of annexin V1 PI2 cells
was reached at 4 h. Western blot analysis showed that acti-
vation of CPP32 (as indicated by the appearance of the p17
subunit) occurred 90 min after the addition of dexametha-
sone (Fig. 5 b). Moreover, this experiment confirmed that
CPP32 activation is a very early event during dexametha-
sone-induced apoptosis since it takes place before the ex-
posure of phosphatidylserine at the cell surface.
Because induction of apoptosis with anti-CD3 is slower
than that observed with dexamethasone (Fig. 1), the rela-
tive number of cells in apoptosis observed during this pro-
cess results from the cumulative effect of spontaneous apop-
tosis that does not involve CPP32 (Fig. 2 a) and anti-CD3
induced apoptosis which induces the activation of CPP32
(Fig. 2 a). To circumvent this caveat we sorted annexin V1
and annexin V2 cells and analyzed the activation of CPP32
in these populations. While p17 is present in viable cells
(annexin V2) it is not detectable in apoptotic or dying cells
(Fig. 5 c). It is likely that p17 is labile and degraded in apop-
totic cells. Indeed, inhibition of the proteasome activates
CPP32 suggesting that the proteasome tightly controls the
turnover of CPP32 (24). Disappearance of P17 also appears
to be a general phenomenon since it is also observed in dexa-
methasone-induced apoptosis. In Fig. 2 A, after 18 and 24 h
of treatment of thymocytes with dexamethasone, we clearly
show that the p17 does not accumulate in dying cells but
rather progressively disappear. We also observed similar re-
sults in different cell types during anti-Fas- (Rhéaume et al.,
manuscript submitted for publication) or ceramide-induced
apoptosis (Alam et al., manuscript in preparation). Alto-
gether these results confirm that activation of CPP32 is a
very early event during anti-CD3 induced apoptosis which
occurs before the loss of membrane asymmetry.
Induction of Negative Selection in the Thymus Activates
CPP32. Exposure to CD3-specific antibodies, in vitro
Figure 4. Inhibition of thy-
mocyte apoptosis by zVAD-
CH2F. In vitro, apoptosis in thy-
mocytes cultured for 18 h at
378C alone (A), with immobi-
lized anti-CD3 mAb (B) or with
dexamethasone (C) is inhibited
by zVAD-CH2F. Cell viability
in the presence (open circles) or
absence (closed circles) of zVAD-
CH2F was determined as in Fig.
1. Cells incubated at 48C were
used as a negative control (open
squares). These experiments were
repeated on two separate occa-
sions with identical results.
Figure 5. The activation of CPP32 is a very early event of thymocyte
apoptosis. (A and B) Thymocytes from C56BL/6 mice were isolated and
incubated with dexamethasone. Samples were taken at 30-min intervals
and analyzed for levels of apoptosis with annexin V-FITC and PI (A).
Cell lysates were submitted to Western blotting analysis for the processing
of CPP32 (B). (C) Thymocytes were cultured for 20 h in the presence of
immobilized anti-CD3 mAb. Cells were then labeled with annexin
V-FITC, and annexin V2 and annexin V1 cells were sorted at 48C with
a FACStarÒ Plus. Sorted cells were lysed and extract contents were ana-
lyzed for processing of CPP32 by Western blotting.1508 Activation of CPP32 during Thymic Negative Selection
and in vivo, stimulates apoptosis predominantly in CD4181
thymocytes (26–30). Based on the above observations it was
tempting to suggest that, in vivo, CPP32 could take an ac-
tive part in TcR-induced negative selection of autoreactive
CD4181 T cells in the thymus. In order to verify this hy-
pothesis, mice expressing an IEk-restricted pigeon cyto-
chrome C (PCC)-specific TcR transgene (AD10) were
injected intraperitoneally with PCC. 24 h after PCC chal-
lenge, the expression of the early activation marker CD69
on isolated thymocytes was only observed in PCC-injected
AD10 mice of the H-2k and not of the H-2b haplotype
(data not shown). Moreover, the thymus cellularity in in-
jected H-2k animals was greatly affected (Fig. 6 A). The
absolute number of CD4181 cells was at least twice lower
in H-2k mice than in H-2b mice. As the absolute number
of CD4182 cells did not differ significantly between the
two types of animals, the drop of CD4181 cell number in
H-2k mice was interpreted as the result of PCC-stimulated
PCD rather than of PCC-induced maturation in CD4182
cells. Altogether these observations indicated that H-2k but
not H-2b thymocytes were stimulated in vivo by PCC and
were undergoing negative selection. Interestingly, the num-
ber of CD4282 cells was always two fold higher in H-2k–
injected mice as compared with H-2b animals. It is known
that, soon after expressing a functional preTcR, CD4282
thymocytes undergo a step of proliferation leading to mat-
uration into the CD4181 stage (31). As in these two types
of mice immature CD4282 thymocytes express the TcR
transgene, it is possible that injection of PCC in H-2k mice
stimulates these cells to proliferate.
Thymocytes isolated from injected mice were placed in
culture medium and incubated at 378C. 18 h later, cell ali-
quots were taken and analyzed by flow cytometry for their
phenotype as well as for evidence of apoptosis. As seen in
Fig. 6 B, among viable cells (annexin V2), the relative per-
centage of CD4181 cells was five times lower in popula-
Figure 6. Injection of PCC induce negative selection and activation of CPP32 in thymocytes of PCC-specific TcR transgenic mice of the H-2k, but
not H-2b, haplotype. (A) Absolute number of cells in the different cell populations of thymuses isolated from H-2k and H-2b TcR transgenic mice 24 h
after PCC injection. (B, top) Percentages of expression of CD4 and CD8 molecules by viable thymocytes (annexin V2) isolated from PCC-injected
H-2k and H-2b TcR transgenic mice after 18 h of culture at 378C. Thymuses from noninjected H-2k TcR transgenic mice contain 34.3 6 2.5% of
CD4182 cells, 48.4 6 5.7% of CD4181 cells and 15.0 6 5.6% of CD4282 cells. Thymuses from noninjected H-2b TcR transgenic mice contain 37.0 6
1.8% of CD4182 cells, 46.0 6 4.1% of CD4181 cells and 14.8 6 3.9% of CD4282 cells. (B, bottom) Percentages of annexin V1 cells in CD4182,
CD4181 and CD4282 thymocytes isolated from PCC-injected H-2k and H-2b TcR transgenic mice after 18 h of culture at 378C. (C) Proteolytic cleav-
age of CPP32 and PARP in thymocytes isolated from PCC-injected H-2k and H-2b TcR transgenic mice. After 6 or 18 h of culture at 378C, cells were
lysed and the lysates were electrophoresed. The substrate cleavage was visualized by immunoblotting as described in Materials and Methods.1509 Alam et al.
tions isolated from H-2k mice than in those issued from
H-2b mice, indicating that PCC injection had induced
specific cell death in CD4181 H-2k thymocytes. The effect
of PCC injection on thymocyte apoptosis was, however,
not restricted to the CD4181 cell subset. Indeed, a twofold
increase in the percentage of annexin V1 cells could be
observed for CD4181 and CD4182 cells isolated from
H-2k mice, while CD4282 cell populations from H-2k
and H-2b animals included the same percentage of annexin
V1 cells (Fig. 6 C). Higher levels of apoptosis in CD4181
and CD4182 cells from PCC-injected H-2k mice was also
noticed in DNA degradation assays using TUNELÒ stain-
ing (data not shown). Similar results were obtained in two
independent experiments including groups of three mice.
Cell lysates from cultures isolated from all H-2k or H-2b
transgenic mice used in our experiments were immuno-
blotted for the detection of CPP32 activation and PARP
cleavage. Freshly isolated thymocytes from mice injected
with PCC did not contain cells expressing activated CPP32
nor were they annexin V1 (Fig. 6 C and data not shown).
This situation may find its explanation in the capacity of
macrophages in vivo to eliminate by phagocytosis cells in
early apoptosis as soon as or before they expose phosphati-
dylserine residues at their surface (32). In contrast, upon in
vitro incubation, cleavage of the 32-kD proenzyme oc-
curred only in thymocytes isolated from H-2k transgenic
animals previously injected with soluble PCC (Fig. 6 C).
This was seen as early as after 6 h of culture in all PCC-
injected H-2k transgenic animals. However, thymocytes
from PCC-injected H-2b mice, although undergoing sponta-
neous apoptosis (Fig. 6 B), did not show any evidence for
CPP32 processing at any time point. This confirmed our
previous observation that spontaneous apoptosis of thymo-
cytes did not involve proteolytic cleavage of CPP32. The
lack of detection of activated CPP32 in H-2b thymocytes
could not be attributed to a lower number of apoptotic cells
than in H-2k cells. Indeed, at identical number of annexin
V1 cells (after 6 h and 18 h of incubation at 378C for H-2k
and H-2b transgenic mice, respectively (data not shown),
no processing of CPP32 could be seen in thymocytes iso-
lated from H-2b transgenic mice while it was readily de-
tectable in cells taken from H-2k animals (Fig. 6 C). In
contrast, cleavage of PARP was seen in both PCC-medi-
ated apoptosis of H-2k thymocytes and during spontaneous
apoptosis of H-2b thymocytes (Fig. 6 C). Taken together
these results support the hypothesis that TcR engagement
during negative selection induced by PCC injection acti-
vates CPP32 in H-2k transgenic mice. They also associate
the cleavage of PARP during spontaneous apoptosis of thy-
mocytes from H-2b mice with the activation of a cysteine
protease distinct from CPP32, but having similar substrate
specificity.
The Caspase Inhibitor zVAD-CH2F Blocks Early Events in
Apoptosis Leading to Negative Selection. To confirm the in-
volvement of CPP32 in negative selection we obtained
apoptotic cells ex vivo after injection of PCC. Parameters
were modified including the duration of PCC treatment
(16 vs. 24 h) and the age of injected mice (3 vs. 5–6 wk).
Under these conditions, we were able to detect substantial
levels of apoptosis ex vivo in thymocytes of transgenic H-2k
mice (13.0 6 0.5% annexin V1 PI2, 12.0 6 3.3% an-
nexin V1 PI1 for H-2k mice) (Fig. 7 A). Control H-2b
mice were injected and studied for levels of apoptotic cells
using the same protocol (1.6 6 0.9% annexin V1 PI2, 1.3 6
0.5% annexin V1 PI1 for H-2b mice). In view of these
results and together with the observation that CPP32 cleav-
age is a very early event of anti-CD3–induced apoptosis,
experiments were carried out to determine if inhibition of
cysteine protease activity could block death of cells already
committed to apoptosis. Thymocytes isolated from PCC-
injected H-2k transgenic mice were then incubated at 378C
in the presence or absence of zVAD-CH2F. As depicted in
Fig. 7 A, zVAD was able to inhibit completely viable cells
(annexin V2 PI2) from undergoing apoptosis. Indeed the
percentage of annexin V2 PI2 remained constant through-
out the experiment (75.0%; Fig. 7 A) while the relative
number of annexin V2 PI2 cells decreased in untreated
cells (61.3%; Fig. 7 A). In contrast this inhibitor did not
prevent the passage of cells from early apoptosis (annexin
V1 PI2) to late apoptosis (annexin V1 PI1) (Fig. 7 A).
This suggests that once thymocytes express phosphati-
dylserine at the upper face of the cell membrane, these are
condemned to die. Moreover these results confirm that
cysteine proteases play a major role during apoptosis before
the loss of membrane asymmetry.
Analysis of CPP32 and PARP confirmed that CPP32 is
Figure 7. zVAD-CH2F blocks early apoptosis and CPP32 activity in
thymocytes undergoing negative selection. 3 wk-old H-2k transgenic
mice were injected with PCC. 16 h later thymocytes were isolated and
cultured with or without zVAD-CH2F. After 6 h, cells were compared
for levels of apoptosis with annexin V-FITC and PI. Cell extracts were
analyzed by Western blotting for processing of CPP32 and cleavage of
PARP.1510 Activation of CPP32 during Thymic Negative Selection
activated during negative selection in vivo as we were able
to detect the p17 of CPP32 and the cleaved 85-Kd form of
PARP in ex vivo isolated thymocytes from PCC injected
H-2k mice (Fig. 7 B). Incubation of the cells at 378C in-
creased the processing of CPP32 and the cleavage of PARP
during the first 6 h. zVAD not only inhibited the process-
ing of cpp32 but it also decreased the intensity of the p17.
Moreover the complete absence of the 85Kd fragment of
PARP clearly confirm that zVAD-CH2F inhibits CPP32
activation. This phenomenon was observed in three differ-
ent animals, confirming that processed forms of these pro-
teins were subjected to further proteolysis.
Discussion
In the present paper the activation of the cysteine pro-
tease CPP32 is shown to be one of the earlier and initiating
events in thymocytes undergoing apoptosis which results from
the crosslinking of cell surface CD3/TcR complexes. Indeed,
we observed that the processing of CPP32 occurs before
the loss of membrane asymmetry in dexamethasone- and
anti-CD3–mediated apoptosis. The ability of caspase inhib-
itors to block the loss of membrane asymmetry, clearly in-
dicates that caspases are part of the enzymatic machinery
which is upstream of cell surface–related events. Moreover,
CPP32 activation and cell death are also observed in thy-
mocytes of PCC-specific TcR transgenic mice previously
injected with PCC. These results indicate that CPP32 is in-
volved in the molecular pathway leading to the clonal dele-
tion of autoreactive cells in the thymus. By contrast, during
apoptosis occurring spontaneously in cultures of thymocytes
at 378C we were unable to detect processing of CPP32.
However, apoptosis at 378C as well as cell death induced
by anti-CD3/TcR ligation were both accompanied by
cleavage of PARP and were both sensitive to the ICE pro-
tease family inhibitor, zVAD-CH2F. This would suggest
the involvement of another CPP32-like cysteine protease
in spontaneous apoptosis of thymocytes.
Our study is the first to show direct activation of the cys-
teine protease, CPP32, in thymocytes during negative se-
lection. Recently, it has been reported that spontaneous
apoptosis and anti-CD3-mediated apoptosis of isolated thy-
mocytes are both sensitive to inhibitors specific to CPP32-
like proteases but not to ICE (33). Moreover, ICE-defi-
cient thymocytes have been shown to undergo normal
negative selection in the thymus (34). These observations
would suggest that only CPP32, or CPP32-like enzymes, but
not ICE-like proteases, are key components of the molecu-
lar processes leading to negative selection of thymocytes. Re-
cently, activation of an unidentified cysteine protease dur-
ing the process of negative selection has been reported (35).
Finally with the knowledge that DNA fragmentation is the
hallmark of apoptosis, the recent observation that CPP32
activate the DNA fragmentation factor demonstrate the
importance of this caspase in the executioner phase of pro-
grammed cell death (36).
Several CPP32-like proteases, such as caspase 6 (Mch2)
(36), caspase 7 (Mch3, ICE-LAP3, CMH-1) (38–40), have
been identified. Whether activation of these proteases con-
stitutes a component of the molecular pathway leading to
thymic negative selection remain to be determined. This
participation could take place either by an activation cascade
of different proteases, as proposed by others using cell-free
system (12), or by a redundant action of different proteases.
The latter proposition finds its substance in the recent ob-
servation made by Flavell and coworkers (41) that thy-
mocytes isolated from CPP32-deficient mice would retain
normal susceptibility to apoptosis induced by combined anti-
CD3 and anti-CD28 mAb treatments. This would imply
that CPP32 is not the only cysteine protease involved in
negative selection of thymocytes. However, whether in
vitro combined anti-CD3 and anti-CD28 crosslinkings in-
duce the same molecular events as those involved in nega-
tive selection of thymocytes in vivo can be questioned.
This is particularly relevant when one considers that nega-
tive selection in CD28-deficient mice appears to be normal
(42). In this context and in line with the observation pre-
sented in the present study, it would be interesting to know
whether CPP32-deficient thymocytes display normal sensi-
tivity to negative selection when challenged with specific
antigen or endogenous superantigen in vivo. The use of
TcR-transgenic CPP32-deficient animals should provide a
direct answer to this important question.
We also observed that CPP32 processing occurs during
apoptosis induced by dexamethasone. Glucocorticoids are
known to affect thymocyte development in several ways.
On one hand they stimulate apoptosis in immature thymo-
cytes and on the other hand they promote the survival of
TcR stimulated cells (43–45). Our observation shows that
the pathway used by glucocorticoids in thymocyte apopto-
sis involves the activation of CPP32. However, the redun-
dant action of other CPP32-like cysteine proteases in this
pathway cannot be ruled out. This is supported by the ob-
servation that thymocytes from CPP32-deficient mice would
exhibit normal sensitivity to dexamethasone-induced cell
death (41).
Finally, we observed that not only CD4181 thymocytes
but also CD4182 thymocytes in H-2k TcR-transgenic mice
were sensitive to PCD induced by injection of PCC. These
results would indicate that CD4182 thymocytes are also
susceptible to the process of negative selection as demon-
strated for superantigens (46). This idea is also supported by
the recent observation made by Kishimoto and Sprent that
CD4182 thymocytes expressing an immature phenotype
(HSAhigh) are sensitive to TcR-mediated apoptosis in vivo
and in vitro (47).
The findings presented in the present paper make two
important points: (a) they correlate for the first time the ac-
tivation of a cysteine protease, CPP32, with the phenome-
non of negative selection of T cells in the thymus and (b)
they show that different types of apoptosis of thymocytes
use pathways involving the activation of different cysteine
proteases. Future studies involving new reagents specific for
these proteases should lead to a more exact definition of
these different death pathways in developing T cells.1511 Alam et al.
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